1,792 results on '"Wargo, Jennifer"'
Search Results
2. Timing is Everything: Neoadjuvant Versus Adjuvant Immunotherapy in Patients with Resectable Metastatic Melanoma
3. Author Correction: Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results
4. Diverse clonal fates emerge upon drug treatment of homogeneous cancer cells
5. Standards for fecal microbiota transplant: Tools and therapeutic advances
6. Targeting PD-L2–RGMb overcomes microbiome-related immunotherapy resistance
7. Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results
8. Embracing cancer complexity: Hallmarks of systemic disease
9. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial
10. Fucosylation of HLA-DRB1 regulates CD4+ T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy
11. Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1.
12. Modulating a prebiotic food source influences inflammation and immune-regulating gut microbes and metabolites: insights from the BE GONE trial
13. Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring
14. English Teaching as an Evangelical Tool for Two-by-Two Missionaries
15. The microbiome and human cancer
16. Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy.
17. MAdCAM-1: a newly identified microbial 'gut check' for T cells
18. Young-onset Rectal Cancer: Unique Tumoral Microbiome and Correlation With Response to Neoadjuvant Therapy
19. Correction: Timing is Everything: Neoadjuvant Versus Adjuvant Immunotherapy in Patients with Resectable Metastatic Melanoma
20. Neoadjuvant relatlimab and nivolumab in resectable melanoma
21. Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome
22. Using gut microorganisms to treat cancer
23. B cells and tertiary lymphoid structures promote immunotherapy response
24. Microbiome and Cancer Metastasis
25. English teaching as an evangelical tool for two-by-two missionaries
26. Bridging the research-practice gap in education: Initiatives from 3 OECD countries.
27. TARO: tree-aggregated factor regression for microbiome data integration
28. Jennifer A. Wargo, Nadim J. Ajami, and Carrie R. Daniel-MacDougall
29. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy
30. Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)
31. Mechanisms of immune activation and regulation: lessons from melanoma
32. Targeting the gut and tumor microbiota in cancer
33. Anti–CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers—Response
34. The Microbiome in Gastrointestinal Cancers
35. Outcomes After Sphincter-Sparing Local Therapy for Anorectal Melanoma: 1989 to 2020
36. Fusobacterium is enriched in oral cancer and promotes induction of programmed death-ligand 1 (PD-L1)
37. Immunotherapy response-associated Akkermansia: canary in a coal mine?
38. Evolution of FMT – From early clinical to standardized treatments
39. Multi-modal molecular programs regulate melanoma cell state
40. Publisher Correction: Targeting PD-L2–RGMb overcomes microbiome-related immunotherapy resistance
41. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis
42. Coenzyme A fuels T cell anti-tumor immunity
43. Abstract B024: Immune exhaustion and reversal of progestin-related immune modulation in adaptive resistance to levonorgestrel intrauterine device for treatment of atypical hyperplasia and early endometrial cancer
44. Androgen drives melanoma invasiveness and metastatic spread by inducing tumorigenic fucosylation
45. Correlation of cancer testis antigen expression with high type-I interferon signal and prognosis in small bowel neuroendocrine tumors.
46. Tumoral microbial and pathway alterations associated with young-onset rectal cancer and its response to therapy.
47. Cancer Associated Bacteria in Primary and Metastatic Non-Small Cell Lung Cancer
48. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
49. Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment
50. Neoadjuvant Systemic Therapy for High-Risk Melanoma Patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.